Edition:
United Kingdom

Aldeyra Therapeutics Inc (ALDX.OQ)

ALDX.OQ on NASDAQ Stock Exchange Capital Market

6.80USD
8:59pm GMT
Change (% chg)

$-0.15 (-2.16%)
Prev Close
$6.95
Open
$7.00
Day's High
$7.05
Day's Low
$6.60
Volume
8,863
Avg. Vol
119,041
52-wk High
$11.90
52-wk Low
$3.80

Latest Key Developments (Source: Significant Developments)

Aldeyra Therapeutics Posts Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS PRESENTS NONINFECTIOUS ANTERIOR UVEITIS PHASE 2 CLINICAL TRIAL DATA TO THE AMERICAN UVEITIS SOCIETY HELD AT THE AMERICAN ACADEMY OF OPHTHALMOLOGY 2017 ANNUAL MEETING.  Full Article

Aldeyra Therapeutics reports Q3 loss per share of $0.32
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Aldeyra Therapeutics Inc :Aldeyra Therapeutics announces third quarter 2017 financial results.Q3 loss per share $0.32.Q3 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S.‍Cash, cash equivalents, and marketable securities were $47.9 million as of September 30, 2017​.  Full Article

Aldeyra ‍announcesd new data for ADX-102 from Phase 2 clinical trials
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Aldeyra Therapeutics Inc :Aldeyra - ‍announced new clinical data for ADX-102 from recently completed Phase 2 clinical trials of dry eye disease and allergic conjunctivitis​.Aldeyra Therapeutics Inc - ‍Aldeyra plans to commence phase 2B clinical testing of ADX-102 in dry eye disease in first half of 2018​.Aldeyra Therapeutics Inc - ‍ADX-102 generated clinically important responses statistically superior to vehicle in patients with allergic conjunctivitis​.Aldeyra Therapeutics Inc - ‍plans to commence Phase 3 clinical testing of ADX-102 in allergic conjunctivitis in first half of 2018​.  Full Article

ALDEYRA THERAPEUTICS PRICES PUBLIC OFFERING OF COMMON STOCK
Tuesday, 14 Feb 2017 

Aldeyra Therapeutics Inc : ALDEYRA THERAPEUTICS INC PRICES PUBLIC OFFERING OF COMMON STOCK .SAYS PUBLIC OFFERING OF 2.22 MILLION COMMON SHARES PRICED AT $4.50 PER SHARE.  Full Article

Aldeyra Therapeutics Inc proposes public offering of common stock
Monday, 13 Feb 2017 

Aldeyra Therapeutics Inc :Aldeyra Therapeutics Inc proposes public offering of common stock.  Full Article

Aldeyra Therapeutics reports Q2 loss per share $0.41
Wednesday, 10 Aug 2016 

Aldeyra Therapeutics Inc : Aldeyra Therapeutics announces second quarter 2016 financial results and provides corporate update . Q2 loss per share $0.41 .Q2 earnings per share view $-0.44 -- Thomson Reuters I/B/E/S.  Full Article

Aldeyra Therapeutics proposes public offering of common stock
Wednesday, 25 May 2016 

Aldeyra Therapeutics : Aldeyra Therapeutics Inc proposes public offering of common stock .Net proceeds to be used for continued development of NS2 and other product candidates, including further clinical testing of NS2.  Full Article

Aldeyra Therapeutics announces positive results from Phase II clinical trials
Monday, 9 May 2016 

Aldeyra Therapeutics Inc : NS2 generally well tolerated; no serious adverse events, consistent with previous Phase I and Phase II clinical trials . No statistical differences among all groups in any clinical endpoint, including anterior chamber cell count and ocular flare . Aldeyra therapeutics announces positive results from phase II clinical trial in subjects with noninfectious anterior uveitis .Quarterly loss per share $0.51.  Full Article

BRIEF-Aldeyra Therapeutics Posts Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data

* ALDEYRA THERAPEUTICS PRESENTS NONINFECTIOUS ANTERIOR UVEITIS PHASE 2 CLINICAL TRIAL DATA TO THE AMERICAN UVEITIS SOCIETY HELD AT THE AMERICAN ACADEMY OF OPHTHALMOLOGY 2017 ANNUAL MEETING Source text for Eikon: Further company coverage: